`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`————————————————
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners
`
`————————————————
`
`Case IPR2016-00710
`Patent 6,331,415
`
`————————————————
`
`
`
`JOINT MOTION TO TERMINATE WITH RESPECT TO MYLAN
`PURSUANT TO 35 U.S.C. § 317(a)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 35 U.S.C. § 317(a), Petitioner Mylan Pharmaceuticals Inc.
`
`(“Mylan” or “Petitioner”) and Patent Owners Genentech, Inc. (“Genentech”) and
`
`City of Hope (collectively, “Patent Owners”) jointly request termination with
`
`respect to Mylan in IPR2016-00710, which is directed to U.S. Patent No.
`
`6,331,415 (the “’415 Patent”).
`
`A.
`
`STATEMENT OF PRECISE RELIEF REQUESTED
`
`Pursuant to 35 U.S.C. § 317(a), Mylan and Patent Owners jointly request
`
`termination with respect to Mylan in this inter partes review pursuant to a
`
`settlement.
`
`II.
`
`STATEMENT OF FACTS
`
`Mylan and Genentech have reached a settlement that resolves the dispute
`
`between Mylan and Patent Owners with respect to this inter partes review
`
`proceeding. A “Joint Request That Settlement Agreement Be Treated as Business
`
`Confidential Information and Kept Separate Pursuant to 35 U.S.C. § 317(b) and 37
`
`C.F.R. § 42.74” is being filed concurrently with this Joint Motion to Terminate
`
`with Respect to Mylan in reference to sealing of the settlement agreement. See 35
`
`U.S.C. § 317(b) (requiring parties to file agreements in writing with the Office).
`
`The Board previously provided authorization to file this motion on March 13,
`
`2017. (3/13/17 A. Kellogg email re IPR2016-00710 – Request to File Motion to
`
`2
`
`Terminate.)
`
`
`
`
`
`
`
`
`
`
`
`A joint motion to terminate generally must “(1) include a brief explanation
`
`as to why termination is appropriate; (2) identify all parties in any related litigation
`
`involving the patents at issue; (3) identify any related proceedings currently before
`
`the Office, and (4) discuss specifically the current status of each such related
`
`litigation or proceeding with respect to each party to the litigation or proceeding.”
`
`Heartland Tanning, Inc. v. Sunless, Inc., IPR2014-00018, Paper 26 at 2 (PTAB
`
`Jul. 28, 2014).
`
`(1) Brief Explanation. Termination with respect to Mylan is appropriate
`
`because Mylan and Genentech have reached a settlement that resolves all disputes
`
`between Mylan and Patent Owners with respect to this proceeding. A “Joint
`
`Request That Settlement Agreement Be Treated as Business Confidential
`
`Information and Kept Separate Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. §
`
`42.74” is being filed concurrently with this Joint Motion to Terminate with Respect
`
`to Mylan in reference to sealing of the settlement agreement.
`
`(2) Related Litigation. There is currently no litigation involving the
`
`challenged patent.
`
`(3)(4) Related Proceeding before the Patent Office and Its Status. On
`
`January 3, 2017, Merck Sharp & Dohme Corp. (“Merck”) was joined as a party to
`
`this inter partes review. (Paper 32 at 5.) The settlement between Mylan and
`
`Genentech does not involve Merck, and this inter partes review would continue
`
`3
`
`
`
`
`
`
`
`
`
`
`
`between Merck and Patent Owners if this Motion to Terminate with Respect to
`
`Mylan is granted.
`
`III. ARGUMENT
`
`The Board should terminate this inter partes review with respect to Mylan as
`
`Mylan and Patent Owners jointly request, for the following reasons.
`
`First, Mylan and Patent Owners have met the statutory requirement that they
`
`file a “joint request” to terminate before the Office “has decided the merits of the
`
`proceeding.” 35 U.S.C. § 317(a). Under section 317(a), an inter partes review
`
`shall be terminated with respect to a party upon such joint request “unless the
`
`Office has decided the merits of the proceeding before the request for termination
`
`is filed.” There are no other preconditions of 35 U.S.C. § 317(a).
`
`Second, Mylan and Genentech have reached a settlement that resolves all
`
`disputes between Mylan and Patent Owners in this proceeding and as to the ’415
`
`Patent. A true copy of the settlement agreement is filed concurrently herewith.
`
`See Ex. 1089. Mylan and Genentech request that the settlement agreement be
`
`treated as business confidential information, and be kept separate from the files of
`
`this proceeding in accordance with 37 C.F.R. § 42.74(c). No other such
`
`agreements, written or oral, exist between or among the parties.
`
`Accordingly, Mylan and Patent Owners in the present proceeding jointly
`
`certify that there are no other written or oral agreements or understandings,
`
`
`4
`
`
`
`
`
`
`
`
`
`including any collateral agreements, between them, including but not limited to
`
`licenses, covenants not to sue, confidentiality agreements, payment agreements, or
`
`other agreements of any kind, that are made in connection with or in contemplation
`
`of, the termination of the instant proceeding.
`
`IV. CONCLUSION
`
`For the foregoing reasons, Mylan and Patent Owners respectfully request
`
`termination with respect to Mylan in this inter partes review of the ’415 Patent.
`
`Respectfully submitted,
`
`/Deanne M. Mazzochi/
`Deanne M. Mazzochi (Reg. No. 50,158)
`
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`Tel: (312) 222-6305
`Fax: (312) 222-6325
`dmazzochi@rmmslegal.com
`
`Counsel for Petitioner Mylan
`Pharmaceuticals Inc.
`
`
`
`Dated: March 13, 2017
`
`5
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh /
`David L. Cavanaugh
`Reg. No. 36,476
`
`David L. Cavanaugh
`WILMER CUTLER PICKERING HALE
` AND DORR LLP
`1875 Pennsylvania Avenue NW
`Washington, DC 20006
`David.Cavanaugh@wilmerhale.com
`Telephone: 202-663-6025
`Facsimile: 202-663-6363
`
`Attorney for Genentech, Inc. & City of
`Hope
`
`
`
`Dated: March 13, 2017
`
`
`
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on March 13, 2017, the
`
`
`
`
`
`foregoing document is being served by E-mail by agreement of the parties to the
`
`following counsel of record:
`
`Heather M. Petruzzi
`Reg. No. 71,270
`Heather.Petruzzi@wilmerhale.com
`Adam R. Brausa
`Reg. No. 60,287
`abrausa@durietangri.com
`Jeffrey P. Kushan
`Reg. No. 43,401
`jkushan@sidley.com
`
`Katherine A. Helm
`SIMPSON THACHER & BARTLETT
`LLP
`425 Lexington Avenue
`New York, NY 10017
`General Tel: (212) 455-2000
`Direct Tel: (212) 455-3647
`Facsimile: (212) 455-2502
`khelm@stblaw.com
`
`David L. Cavanaugh
`Reg. No. 36,476
`WILMER CUTLER PICKERING HALE
` AND DORR LLP
`1875 Pennsylvania Avenue NW
`Washington, DC 20006
`David.Cavanaugh@wilmerhale.com
`Telephone: 202-663-6025
`Facsimile: 202-663-6363
`
`Raymond N. Nimrod
`Reg. No. 31,987
`QUINN EMANUEL URQUHART &
` SULLIVAN, LLP
`51 Madison Ave., 22nd Floor
`New York, NY 10010
`raynimrod@quinnemanuel.com
`
`Matthew A. Traupman
`Reg. No. 50,832
`matthewtraupman@quinnemanuel.com
`
`
`
`
`
`
`7
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
` /Deanne M. Mazzochi/
`Deanne M. Mazzochi (Reg. No. 50,158)
`dmazzochi@rmmslegal.com
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`Telephone: (312) 222-6305
`Facsimile: (312) 222-6325
`
`8
`
`
`
`Dated: March 13, 2017
`
`
`
`
`
`
`
`
`
`
`
`